Alessandro Testori

33.3k total citations · 2 hit papers
213 papers, 9.4k citations indexed

About

Alessandro Testori is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Alessandro Testori has authored 213 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Oncology, 88 papers in Molecular Biology and 55 papers in Immunology. Recurrent topics in Alessandro Testori's work include Cutaneous Melanoma Detection and Management (104 papers), Melanoma and MAPK Pathways (57 papers) and CAR-T cell therapy research (45 papers). Alessandro Testori is often cited by papers focused on Cutaneous Melanoma Detection and Management (104 papers), Melanoma and MAPK Pathways (57 papers) and CAR-T cell therapy research (45 papers). Alessandro Testori collaborates with scholars based in Italy, United States and France. Alessandro Testori's co-authors include Alexander M.M. Eggermont, Michele Maio, Caroline Robert, Vanna Chiarion‐Sileni, Stefan Suciu, Jean‐Jacques Grob, Claus Garbe, Mario Santinami, Ulrich Keilholz and Reinhard Dummer and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Alessandro Testori

209 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

2015 371 citations Célèste Lebbé, Ketty Peris et al. European Journal of Cancer profile →
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

2015 340 citations Claus Garbe, Célèste Lebbé et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Testori Italy	53	6.0k	3.6k	2.6k	1.5k	964	213	9.4k
Antônio C. Buzaid United States	39	8.0k 1.3×	4.2k 1.2×	2.6k 1.0×	1.8k 1.2×	985 1.0×	139	10.4k
John A. Thompson United States	40	9.2k 1.5×	3.4k 1.0×	4.3k 1.6×	1.7k 1.1×	808 0.8×	111	12.4k
Jane L. Messina United States	53	5.6k 0.9×	2.9k 0.8×	2.1k 0.8×	1.8k 1.2×	1.1k 1.2×	260	9.6k
Alan Spatz France	45	4.7k 0.8×	3.4k 1.0×	1.8k 0.7×	863 0.6×	851 0.9×	200	7.7k
Svetomir N. Markovic United States	60	6.9k 1.1×	3.4k 0.9×	4.0k 1.5×	988 0.6×	594 0.6×	349	12.2k
Mohammed Kashani–Sabet United States	47	4.5k 0.7×	3.9k 1.1×	1.3k 0.5×	1.4k 0.9×	1.1k 1.2×	182	7.7k
Mark B. Faries United States	42	5.9k 1.0×	2.6k 0.7×	2.2k 0.8×	1.5k 1.0×	570 0.6×	173	7.5k
Mario Santinami Italy	42	5.0k 0.8×	3.2k 0.9×	2.5k 1.0×	978 0.6×	474 0.5×	166	7.9k
Stanley P. L. Leong United States	43	4.4k 0.7×	2.4k 0.7×	1.1k 0.4×	1.1k 0.7×	526 0.5×	221	6.9k
Karl D. Lewis United States	41	4.9k 0.8×	4.0k 1.1×	1.5k 0.6×	1.5k 1.0×	1.0k 1.1×	177	7.8k

Countries citing papers authored by Alessandro Testori

Since Specialization

Citations

This map shows the geographic impact of Alessandro Testori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Testori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Testori more than expected).

Fields of papers citing papers by Alessandro Testori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Testori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Testori. The network helps show where Alessandro Testori may publish in the future.

Co-authorship network of co-authors of Alessandro Testori

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Testori. A scholar is included among the top collaborators of Alessandro Testori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Testori. Alessandro Testori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Christian U. Blank, Alexander M.M. Eggermont, et al.. (2023). The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022. Journal of Translational Medicine. 21(1). 265–265. 2 indexed citations

Eggermont, Alexander M.M., Vanna Chiarion‐Sileni, Jean-Jacques Grob, et al.. (2019). Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer. 119. 1–10. 123 indexed citations

Ascierto, Paolo A., Paolo Bruzzi, Alexander M.M. Eggermont, et al.. (2019). The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018. Journal of Translational Medicine. 17(1). 148–148. 1 indexed citations

Testori, Alessandro, Simone Ribero, Alice Indini, & Mario Mandalà. (2019). Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. American Journal of Clinical Dermatology. 20(6). 817–827. 30 indexed citations

Testori, Alessandro, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 8. 440–440.

Bartolini, Alice, Simona Lamba, Daniele Oddo, et al.. (2016). BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research. 22(19). 4923–4933. 51 indexed citations

Testori, Alessandro, Javier Soteldo, B. Powell, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 7. 294–294. 6 indexed citations

Eggermont, Alexander M.M., Stefan Suciu, Piotr Rutkowski, et al.. (2016). Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European Journal of Cancer. 55. 111–121. 54 indexed citations

Gandini, Sara, Maurizio Montella, Carlo Riccardo Rossi, et al.. (2016). Sun exposure and melanoma prognostic factors. Oncology Letters. 11(4). 2706–2714. 21 indexed citations

10.

Stanganelli, Ignazio, Paolo A. Ascierto, R. Bono, et al.. (2013). Impact of Mole Mapping in the Italian Health System. Dermatology. 226(Suppl. 1). 13–17. 2 indexed citations

11.

Mozzillo, Nicola, Elisabetta Pennacchioli, Sara Gandini, et al.. (2013). Sentinel Node Biopsy in Thin and Thick Melanoma. Annals of Surgical Oncology. 20(8). 2780–2786. 52 indexed citations

12.

Campana, L, Alessandro Testori, Nicola Mozzillo, & Carlo Riccardo Rossi. (2013). Treatment of metastatic melanoma with electrochemotherapy. Journal of Surgical Oncology. 109(4). 301–307. 38 indexed citations

13.

Eggermont, Alexander M.M., Stefan Suciu, Alessandro Testori, et al.. (2012). Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. Journal of Clinical Oncology. 30(31). 3810–3818. 190 indexed citations

14.

Pennacchioli, Elisabetta, Giulio Tosti, Massimo Barberis, et al.. (2012). Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?. Clinical & Experimental Metastasis. 29(7). 757–773. 25 indexed citations

15.

Maio, Michele, Paolo A. Ascierto, Alessandro Testori, et al.. (2012). The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental & Clinical Cancer Research. 31(1). 91–91. 26 indexed citations

16.

Testori, Alessandro, Marco Rastrelli, Elvio De Fiori, et al.. (2010). Radio-guided ultrasound lymph node localization: feasibility of a new technique for localizing and excising nonpalpable lymph nodes ultrasound suspicious for melanoma metastases. Melanoma Research. 20(3). 197–202. 10 indexed citations

17.

Testori, Alessandro, Javier Soteldo, Daniele Sances, et al.. (2009). Cutaneous melanoma in the elderly. Melanoma Research. 19(3). 125–134. 18 indexed citations

18.

Rocca, Andrea, Saverio Minucci, Giulio Tosti, et al.. (2009). A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British Journal of Cancer. 100(1). 28–36. 67 indexed citations

19.

Cascinelli, Natale, Filiberto Belli, Mario Santinami, et al.. (2000). Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience. Annals of Surgical Oncology. 7(6). 469–474. 251 indexed citations

20.

Cascinelli, N., Mario Santinami, Alessandro Testori, & Filiberto Belli. (1990). Surgical treatment of cutaneous melanoma. 3(2). 57–67. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact